Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Written By Michael Gary Scott



Intriguing Stock Moves: Notable Insider Trading Under $2

Insights into Penny Stocks

When insiders make moves in the stock market, it’s akin to revealing pages from a company’s diary, shedding light on their faith or fears in the venture’s future. Investors dabbling in penny stocks often view insider transactions as a beacon, illuminating potential paths for their investments.

Blue Star Foods: A Sea of Opportunities

Steering our ship towards Blue Star Foods Corp., Director Nubar Herian recently embarked on a notable voyage, acquiring 219,611 shares at an average price of $0.14 each. This maritime move set sail with an expenditure of approximately $30,636. On the horizon of February 21, Blue Star Foods cast a net with a master service agreement alongside a seafood value-added provider. Based in Miami, this company specializes in importing, packaging, and distributing refrigerated pasteurized crab meat and other premium seafood products.

Ekso Bionics: The Mechanical Marvel

Next in our trading tales, Ekso Bionics Holdings, Inc. witnessed Director Corinna Lathan securing 13,733 shares at an average price of $1.13, investing around $15,477 in this endeavor. March 4 marked a pivotal point for Ekso Bionics as they unveiled mixed fourth-quarter financial results. Known for their exoskeleton technology catering to healthcare and industrial markets, Ekso Bionics continues to carve a niche with their innovative creations.

Cognition Therapeutics: Illuminating the Path Ahead

Our final spotlight falls upon Cognition Therapeutics, Inc., where CEO and President Lisa Ricciardi unveiled a strategic move by acquiring 5,700 shares at an average price of $1.75, amounting to an investment of approximately $9,975. The recent announcement of the closing of an $11.5 million public offering of common stock marked a significant milestone for Cognition Therapeutics. Delving into the realm of clinical-stage biopharmaceuticals, this company is dedicated to pioneering small-molecule therapeutics aimed at combating age-related degenerative diseases and central nervous system disorders.

See also  Ford (NYSE:F) Gains after Revealing New Pickup